BVI Receives FDA Approval for Finevision HP Trifocal IOL

BVI announced that the FDA has approved its Finevision HP trifocal IOL. 

According to BVI, Finevision HP was the world’s first trifocal IOL, with more than 15 years of clinical success and millions of implantations worldwide. Finevision HP was developed through the work of Christophe Pagnoulle, BVI’s Director of R&D, and Damien Gatinel, MD, PhD, ophthalmologist and vision science innovator.

“The development of Finevision HP was a pivotal moment for ophthalmology, reshaping expectations for vision correction after cataract surgery,” said Dr. Damien Gatinel, co-developer and ophthalmologist. “FDA approval in the US means even more patients will benefit from this breakthrough technology.”

The lens is recognized for its patented diffractive optic design that delivers balanced vision at far, intermediate, and near distances. Now in its third generation, the Finevision HP incorporates BVI’s proprietary POD platform and CoPODize technology, harmonizing light distribution and minimizing visual disturbances. Its double C-loop, four-point haptic design ensures long-term stability and precise centration within the capsular bag.

“Finevision HP redefined premium cataract surgery and continues to set the gold standard in premium IOL innovation,” said Shervin Korangy, President and CEO of BVI. “This FDA approval marks a pivotal step in expanding our IOL portfolio in the United States, supporting our mission to deliver best-in-class visual outcomes for patients globally.”

BVI said it has invested in significant capacity expansion to support the US market. The company will execute a phased rollout of the Finevision HP over the coming year, ensuring high-quality manufacturing and surgeon support.

BVI will showcase the Finevision HP trifocal IOL at the American Academy of Ophthalmology (AAO) annual meeting, October 18–20, in Orlando (Booth No. 3521).